Australia's most trusted
source of pharma news
Posted 31 October 2025 AM
There has been a shake-up in the list of exclusive brands with the highest PBS reimbursements this quarter as two huge medicines faced biosimilar competition for the first time.
Johnson & Johnson's Stelara was joined on the PBS by Celltrion's SteQeyma in August. Due to the way the PBS reports reimbursements the two cannot be separated, but combined they earned $93.9 million in pre-rebate R/PBS reimbursements for the third quarter of 2025, a 21.7 per cent fall compared to the same period in 2024, and 35.1 per cent less than Stelara earned in the prior quarter.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.